

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Highly Specialised Technology Evaluation

Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura ID1185

Provisional stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Sanofi (caplacizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Sick Children • African Health Policy Network • Black Health Agency • British Liver Trust • Children’s Liver Disease Foundation • Genetic Alliance UK • Haemophilia Society • HIV i-base • Liver4Life • Muslim Council of Britain • Nam publications • National AIDs Trust • National Children's Bureau • Positively UK • South Asian Health Foundation • Specialised Healthcare Alliance • Terrence Higgins Trust • TTP Network <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for the Study of the Liver • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatric Society • British Psychological Society • British Society for Haematology • Haemophilia Nurses Association • National Blood Service 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services – Jehovah’s Witnesses • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Baxter healthcare (cyclophosphamide) • Roche (rituximab) • Hospira UK (vincristine) • Sandoz (cyclophosphamide, rituximab) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Foundation for Liver Research • Genomics England • MRC Clinical Trials Unit

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Royal College of Obstetricians and Gynaecologists • UK Forum on Haemoglobin Disorders • UK Haemophilia Centre Doctors' Organisation • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Blackpool CCG • NHS Harrogate & Rural District CCG • Welsh Government 	<ul style="list-style-type: none"> • Intensive Care National Audit & Research Centre • National Institute for Health Research • UK TTP registry <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the recommendations.

All non-company/sponsor consultees are invited to make an evidence submission or submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the recommendations.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final evaluation documentation for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company/sponsor commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.